{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T20:43:37Z","timestamp":1773866617204,"version":"3.50.1"},"reference-count":25,"publisher":"The Journal of Rheumatology","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2009,5]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>To assess the frequency of clinical remission in a cohort of patients with systemic juvenile idiopathic arthritis (JIA) who received continuous anti-tumor necrosis factor (TNF) therapy; and to identify potential predictors of remission.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>Patients with systemic JIA who were treated with anti-TNF agents for &gt; 6 months were studied. Demographic and nosologic variables recorded at the start of anti-TNF therapy were analyzed. Association between early variables and occurrence of remission was evaluated through Cox proportional hazard regression analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Forty-five patients were included (30 girls), median age 9 years (range 2\u201317 yrs), age at disease onset 5 years (range 0.5\u201315), disease duration 3 years (range 0.5\u201313). Twenty-one (47%) children showed systemic symptoms at the start of anti-TNF therapy. Patients received therapy for 24 months (range 6\u201388): 45 (100%) were given etanercept, 17 (38%) infliximab, and 5 (11%) adalimumab, in combination with methotrexate. Anti-TNF switching was performed in 22 (49%) children. Eleven (24%) met definition criteria for remission while taking etanercept (n = 8), infliximab (2), or adalimumab (1). Remission occurred following 26 (range 9\u201365) months of therapy. Flares occurred in 5 (45%) patients 2 to 14 months after remission was first recorded. Absence of systemic symptoms at the start of therapy and fulfilment of improvement criteria at Month 3 were associated with remission in univariate analysis; no variable showed any association in multivariate analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>Twenty-four percent of patients with systemic JIA experienced remission with anti-TNF therapy, but only 13% experienced sustained benefit.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.090952","type":"journal-article","created":{"date-parts":[[2009,5,12]],"date-time":"2009-05-12T20:14:10Z","timestamp":1242159250000},"page":"1078-1082","source":"Crossref","is-referenced-by-count":67,"title":["Clinical Remission in Patients with Systemic Juvenile Idiopathic Arthritis Treated with Anti-Tumor Necrosis Factor Agents"],"prefix":"10.3899","volume":"36","author":[{"given":"RICARDO A.G.","family":"RUSSO","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MAR\u00cdA M.","family":"KATSICAS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2009,5,12]]},"reference":[{"key":"2018112909192534000_36.5.1078.1","doi-asserted-by":"crossref","unstructured":"Petty RE Cassidy JT . Systemic arthritis. In: Cassidy JT Petty RE Laxer RM Lindsley CB , editors. Textbook of pediatric rheumatology. 5th ed. Philadelphia: Elsevier Saunders; 2005:291\u00e2\u0080\u0093303.","DOI":"10.1016\/B978-1-4160-0246-8.50018-8"},{"key":"2018112909192534000_36.5.1078.2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10885"},{"issue":"Suppl","key":"2018112909192534000_36.5.1078.3","first-page":"S481","article-title":"Treatment of systemic onset juvenile rheumatoid arthritis (SOJRA) with etanercept: A follow-up study [abstract]","volume":"46","author":"Kimura","year":"2002","journal-title":"Arthritis Rheum"},{"key":"2018112909192534000_36.5.1078.4","first-page":"723","article-title":"Etanercept in systemic juvenile idiopathic arthritis","volume":"20","author":"Russo","year":"2002","journal-title":"Clin Exp Rheumatol"},{"key":"2018112909192534000_36.5.1078.5","first-page":"545","article-title":"Use of infliximab in patients with systemic juvenile idiopathic arthritis refractory to etanercept","volume":"23","author":"Katsicas","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"2018112909192534000_36.5.1078.6","doi-asserted-by":"publisher","DOI":"10.1002\/art.21885"},{"key":"2018112909192534000_36.5.1078.7","first-page":"2290","article-title":"Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis","volume":"31","author":"Wallace","year":"2004","journal-title":"J Rheumatol"},{"key":"2018112909192534000_36.5.1078.8","doi-asserted-by":"publisher","DOI":"10.1002\/art.23141"},{"key":"2018112909192534000_36.5.1078.9","doi-asserted-by":"publisher","DOI":"10.1002\/art.23247"},{"key":"2018112909192534000_36.5.1078.10","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.014886"},{"key":"2018112909192534000_36.5.1078.11","doi-asserted-by":"crossref","unstructured":"Prince FH Twilt M ten Cate R . Long-term follow-up on effectiveness and safety of etanercept in JIA: the Dutch national register. Ann Rheum Dis 2008 Apr 15. [Epub ahead of print]","DOI":"10.1136\/ard.2007.087411"},{"key":"2018112909192534000_36.5.1078.12","first-page":"390","article-title":"International League of Associations of Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"key":"2018112909192534000_36.5.1078.13","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/art.1790110509","article-title":"Cross-cultural adaptation and validation of an Argentine-Spanish version of the Stanford Childhood Health Assessment Questionnaire (CHAQ)","volume":"11","author":"Moroldo","year":"1998","journal-title":"Arthritis Care Res"},{"key":"2018112909192534000_36.5.1078.14","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1002\/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R","article-title":"Preliminary definition of improvement in juvenile arthritis","volume":"40","author":"Giannini","year":"1997","journal-title":"Arthritis Rheum"},{"key":"2018112909192534000_36.5.1078.15","doi-asserted-by":"crossref","unstructured":"Cassidy JT Petty RE . Chronic arthritis in children. In: Cassidy JT Petty RE Laxer RM Lindsley CB , editors. Textbook of pediatric rheumatology. 5th ed. Philadelphia: Elsevier Saunders; 2005:206\u00e2\u0080\u009360.","DOI":"10.1016\/B978-1-4160-0246-8.50015-2"},{"key":"2018112909192534000_36.5.1078.16","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1084\/jem.20050473","article-title":"Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade","volume":"20","author":"Pascual","year":"2005","journal-title":"J Exp Med"},{"key":"2018112909192534000_36.5.1078.17","doi-asserted-by":"publisher","DOI":"10.1002\/art.23437"},{"key":"2018112909192534000_36.5.1078.18","doi-asserted-by":"publisher","DOI":"10.1002\/art.10444"},{"key":"2018112909192534000_36.5.1078.19","first-page":"491","article-title":"Systemic onset juvenile idiopathic arthritis: a retrospective study of 80 consecutive patients followed for 10 years","volume":"27","author":"Lomater","year":"2000","journal-title":"J Rheumatol"},{"key":"2018112909192534000_36.5.1078.20","first-page":"1989","article-title":"Disease course and outcome in juvenile rheumatoid arthritis in a multicenter cohort","volume":"29","author":"Oen","year":"2002","journal-title":"J Rheumatol"},{"key":"2018112909192534000_36.5.1078.21","first-page":"579","article-title":"Remission in juvenile chronic arthritis: a cohort study of 683 consecutive cases with a mean 10 year followup","volume":"30","author":"Fantini","year":"2003","journal-title":"J Rheumatol"},{"key":"2018112909192534000_36.5.1078.22","first-page":"1122","article-title":"Early disease course and predictors of disability in juvenile rheumatoid arthritis and juvenile spondyloarthropathy: a 3 year prospective study","volume":"32","author":"Selvaag","year":"2005","journal-title":"J Rheumatol"},{"key":"2018112909192534000_36.5.1078.23","doi-asserted-by":"publisher","DOI":"10.1002\/art.21774"},{"key":"2018112909192534000_36.5.1078.24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60454-7"},{"key":"2018112909192534000_36.5.1078.25","doi-asserted-by":"publisher","DOI":"10.1002\/art.20242"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.090952","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T03:30:38Z","timestamp":1589772638000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.090952"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":25,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2009,5,12]]},"published-print":{"date-parts":[[2009,5]]}},"alternative-id":["10.3899\/jrheum.090952"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.090952","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,5]]}}}